Mon, Jul 28, 2014, 7:09 AM EDT - U.S. Markets open in 2 hrs 21 mins

Recent

% | $
Click the to save as a favorite.

Exelixis, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • wilderguide wilderguide Oct 21, 2011 2:53 PM Flag

    Oct 27th announcement

    .......

    With so many material events on the immediate horizon, I can't imagine that there can be a single planned date of information release. There's simply too much to try to keep a lid on...

    Particularly to simply coincide with a Qtrly earnings report that we can all agree should be EXEL's best in several years.

    If the MTC results were in-hand today, what would be the benefit to witholding public disclosure beyond Monday's market close?

    Nope... I think we'll see something prior to Thursday's earnings report.
    GLTA

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • OK, you are on.

      The MTC results if positive are not that much of a mover.

      We all know about the Q3 numbers. Just seemed like a good PR move to include both.

      • 2 Replies to jferrazano
      • "The MTC results if positive are not that much of a mover."
        It would certainly bring a great deal of credibility to Exel. It would get a great deal of notice. It can only be good.

      • I would tend to disagree regarding the perspective about the MTC results. Even though the patient population isn't as large it would still lead to filing for approval and hopefully receive approval. Both of these events would likely occur before results of the new CRPC trial. A proven and approved drug is still better than a drug in another phase three trial waiting for results.

        If the results aren't released before the 27th then I'm thinking after. I don't think they will anounce on the same day.

 
EXEL
4.19-0.02(-0.48%)Jul 25 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.